Follow-up in Rivaroxaban Patients in Setting of Thromboembolism

Launched by KING'S COLLEGE HOSPITAL NHS TRUST · Sep 22, 2014

Keywords

ClinConnect Summary

United Kingdom-only prospective, non-interventional, investigator-led, multi-centre, single cohort, registry. The observation period for each patient covers the treatment period with rivaroxaban and follow up until study end. For each patient, the treating health care professional records patient demographics, medical history, signs and symptoms, diagnosis, treatment and safety parameters at an initial visit and subsequent follow-up visit(s). Data monitoring will be undertaken by the Sponsor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or older with an objectively verified diagnosis of DVT and/or PE and treated according to routine clinical practice with Rivaroxaban
• Exclusion Criteria:
• • Patients in whom follow-up is unlikely or impossible
• • Patients unable to give consent
• • Patients who receive heparin therapy for more than 48 hours
• • Patients who receive more than one dose of warfarin
• • Patients with an indication for anticoagulation other than DVT and/or PE
• • All contraindications listed in the local product information (SmPC) will form part of the exclusion criteria